204 related articles for article (PubMed ID: 36816347)
21. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
[TBL] [Abstract][Full Text] [Related]
22. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
23. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
[TBL] [Abstract][Full Text] [Related]
24. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
[TBL] [Abstract][Full Text] [Related]
25. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Arai H; Xiao Y; Millstein J; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Parikh AR; Lenz HJ
Br J Cancer; 2022 Jan; 126(1):72-78. PubMed ID: 34689170
[TBL] [Abstract][Full Text] [Related]
26. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Schirripa M; Zhang W; Heinemann V; Cao S; Okazaki S; Yang D; Loupakis F; Berger MD; Ning Y; Miyamoto Y; Suenaga M; Gopez RF; West JD; Hanna D; Barzi A; Falcone A; Stintzing S; Lenz HJ
Int J Cancer; 2017 Jul; 141(2):383-392. PubMed ID: 28369940
[TBL] [Abstract][Full Text] [Related]
27. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
[TBL] [Abstract][Full Text] [Related]
28. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang D; Ning Y; Matsusaka S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; West JD; Gopez R; Akihito T; Ichikawa W; Heinemann V; DePaolo RW; Lenz HJ
Int J Cancer; 2017 Sep; 141(6):1222-1230. PubMed ID: 28569041
[TBL] [Abstract][Full Text] [Related]
30. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
[TBL] [Abstract][Full Text] [Related]
31. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
[TBL] [Abstract][Full Text] [Related]
32. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
33. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
[TBL] [Abstract][Full Text] [Related]
34. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.
Sunakawa Y; Stintzing S; Cao S; Heinemann V; Cremolini C; Falcone A; Yang D; Zhang W; Ning Y; Stremitzer S; Matsusaka S; Yamauchi S; Parekh A; Okazaki S; Berger MD; Graver S; Mendez A; Scherer SJ; Loupakis F; Lenz HJ
Ann Oncol; 2015 Dec; 26(12):2450-6. PubMed ID: 26416897
[TBL] [Abstract][Full Text] [Related]
35. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.
Volz NB; Hanna DL; Stintzing S; Zhang W; Yang D; Cao S; Ning Y; Matsusaka S; Sunakawa Y; Berger MD; Cremolini C; Loupakis F; Falcone A; Lenz HJ
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33065994
[TBL] [Abstract][Full Text] [Related]
37. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S; Rosati G; Nasti G; Lonardi S; Zaniboni A; Marchetti P; Leone F; Bilancia D; Iaffaioli RV; Zagonel V; Giordano M; Corsi DC; Ferraú F; Labianca R; Ronzoni M; Scartozzi M; Galli F;
Eur J Cancer; 2017 Sep; 83():106-115. PubMed ID: 28735067
[TBL] [Abstract][Full Text] [Related]
38. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
39. Retrospective Comparative Analysis of KRAS G12C
Giampieri R; Lupi A; Ziranu P; Bittoni A; Pretta A; Pecci F; Persano M; Giglio E; Copparoni C; Crocetti S; Mandolesi A; Faa G; Coni P; Scartozzi M; Berardi R
Front Oncol; 2021; 11():736104. PubMed ID: 34660299
[TBL] [Abstract][Full Text] [Related]
40. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
Suenaga M; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Heinemann V; Lenz HJ
Eur J Cancer; 2019 Jan; 107():100-114. PubMed ID: 30554073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]